HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Chunlizhengda Medical Instruments (1858.HK/688236.CH) - 2023 Full-Year Results May Be Disappointing

United Laboratories International Holdings Placement (3933.HK) - Valuation Pullback Seems Inevitable

BeiGene (6160.HK/BGNE.US) - The Truth Behind Novartis' Divorce Decision on PD-1

China Healthcare Weekly (Aug11)-Anti-Corruption Update, Increase A-Share Shareholder Return, CanSino

China Healthcare Weekly (Aug.25) - Anti Corruption Affects IPO, TIGIT Revives Again? Neusoft Xikang

Anti-Corruption in China Healthcare – the Impact and the Outlook

China Traditional Chinese Medicine (570.HK) - The Privatization Rumor and the Outlook

Thematic (Sector/Industry)

Hong kong Healthcare equipment and services / Thematic (Sector/Industry)

<ul>
<li>The People's Daily/National Health Commission made "mild" statements about anti-corruption, bringing investors “hope”. However, it depends on the attitude of Central Commission for Discipline Inspection, who is the decision maker. </li>
<li>We break down some industry data to help investors better understand the impact of anti-corruption campaign on China healthcare. It seems inevitable that companies’ Q3 performance would be affected.</li>
<li>Looking ahead, companies’ performance reversal may not be as fast as expected.The anti-corruption campaign could accelerate the next stage of reform. Investors need to be prepared for upcoming new changes.  </li>
</ul>


The People's Daily/National Health Commission made "mild" statements about anti-corruption, bringing investors “hope”. However, it depends on the attitude of Central Commission for Discipline Inspection, who is the decision maker. 
We break down some industry data to help investors better understand the impact of anti-corruption campaign on China healthcare. It seems inevitable that companies’ Q3 performance would be affected.
Looking ahead, companies’ performance reversal may not be as fast as expected.The anti-corruption campaign could accelerate the next stage of reform. Investors need to be prepared for upcoming new changes.  


Turnaround in China Healthcare Anti-Corruption: Impact on Company’s 2023 Results & Upcoming New Reforms